Literature DB >> 22833814

A millimeter miss is as good as a thousand miles: The role of accurate target localization in lung stereotactic body radiation therapy.

Allan Y Chen, Michelle B Chen, Yi-Jen Chen.   

Abstract

Year:  2012        PMID： 22833814      PMCID： PMC3378234          DOI： 10.3978/j.issn.2072-1439.2012.03.12

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  10 in total

Review 1.  Involved-field radiotherapy alone for early-stage non-small-cell lung cancer.

Authors:  P C Cheung; W J Mackillop; P Dixon; M D Brundage; Y M Youssef; S Zhou
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-10-01       Impact factor: 7.038

2.  Acquiring a four-dimensional computed tomography dataset using an external respiratory signal.

Authors:  S S Vedam; P J Keall; V R Kini; H Mostafavi; H P Shukla; R Mohan
Journal:  Phys Med Biol       Date:  2003-01-07       Impact factor: 3.609

3.  Stereotactic body radiation therapy for inoperable early stage lung cancer.

Authors:  Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy
Journal:  JAMA       Date:  2010-03-17       Impact factor: 56.272

4.  Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study.

Authors:  Hiroshi Onishi; Hiroki Shirato; Yasushi Nagata; Masahiro Hiraoka; Masaharu Fujino; Kotaro Gomi; Yuzuru Niibe; Katsuyuki Karasawa; Kazushige Hayakawa; Yoshihiro Takai; Tomoki Kimura; Atsuya Takeda; Atsushi Ouchi; Masato Hareyama; Masaki Kokubo; Ryusuke Hara; Jun Itami; Kazunari Yamada; Tsutomu Araki
Journal:  J Thorac Oncol       Date:  2007-07       Impact factor: 15.609

5.  Baseline pulmonary function as a predictor for survival and decline in pulmonary function over time in patients undergoing stereotactic body radiotherapy for the treatment of stage I non-small-cell lung cancer.

Authors:  Mark Henderson; Ronald McGarry; Constantin Yiannoutsos; Achilles Fakiris; David Hoopes; Mark Williams; Robert Timmerman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-04-18       Impact factor: 7.038

Review 6.  Critical review of nonsurgical treatment options for stage I non-small cell lung cancer.

Authors:  Cornelis J A Haasbeek; Suresh Senan; Egbert F Smit; Marinus A Paul; Ben J Slotman; Frank J Lagerwaard
Journal:  Oncologist       Date:  2008-03

Review 7.  Surgery for non-small cell lung cancer: systematic review and meta-analysis of randomised controlled trials.

Authors:  G Wright; R L Manser; G Byrnes; D Hart; D A Campbell
Journal:  Thorax       Date:  2006-01-31       Impact factor: 9.139

8.  Radiotherapy alone for medically inoperable stage I non-small-cell lung cancer: the Duke experience.

Authors:  G S Sibley; T A Jamieson; L B Marks; M S Anscher; L R Prosnitz
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-01-01       Impact factor: 7.038

9.  Double CT imaging can measure the respiratory movement of small pulmonary tumors during stereotactic ablative radiotherapy.

Authors:  Ge Shen; Ying-Jie Wang; Hong-Guo Sheng; Xiao-Ping Duan; Jun-Liang Wang; Wei-Jing Zhang; Zhen-Shan Zhou; Guang-Ying Zhu; Ting-Yi Xia
Journal:  J Thorac Dis       Date:  2012-04-01       Impact factor: 2.895

10.  The IASLC Lung Cancer Staging Project: proposals for the revision of the N descriptors in the forthcoming seventh edition of the TNM classification for lung cancer.

Authors:  Valerie W Rusch; John Crowley; Dorothy J Giroux; Peter Goldstraw; Jung-Gi Im; Masahiro Tsuboi; Ryosuke Tsuchiya; Johan Vansteenkiste
Journal:  J Thorac Oncol       Date:  2007-07       Impact factor: 15.609
  10 in total
  1 in total

1.  DNA topoisomerase I drugs and radiotherapy for lung cancer.

Authors:  Allan Y Chen; Patricia M T Chen; Yi-Jen Chen
Journal:  J Thorac Dis       Date:  2012-08       Impact factor: 2.895
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.